The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer

Biomaterials

Volumn 34, Issue 14, 2013, Pages 3626-3638

  Zhou, Jia ^a   Zhao, Wei Yu ^a   Ma, Xu ^a   Ju, Rui Jun ^a   Li, Xiu Ying ^a   Li, Nan ^a   Sun, Meng Ge ^a   Shi, Ji Feng ^a   Zhang, Cheng Xiang ^a   Lu, Wan Liang ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Anticancer efficacy; Mitochondrial signaling pathway; Resistant lung cancer; Targeting paclitaxel liposomes; TPGS1000 TPP conjugate

Indexed keywords

ANTICANCER EFFICACY; LUNG CANCER; MITOCHONDRIAL SIGNALING PATHWAYS; PACLITAXEL; TPGS1000-TPP CONJUGATE;

BIOLOGICAL ORGANS; CELL DEATH; CHEMOTHERAPY; ENZYME INHIBITION; LIPOSOMES; MITOCHONDRIA; PIGMENTS; PROTEINS; SYNTHESIS (CHEMICAL);

DISEASES;

CASPASE 3; CASPASE 9; CYTOCHROME C; LIPOSOME; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELLULAR PARAMETERS; CELLULAR UPTAKE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG CANCER; MITOCHONDRION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RESISTANT LUNG CANCER; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYTOCHROMES C; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MITOCHONDRIA; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84875236608     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.078     Document Type: Article

References (44)

1. Tiwari G., Tiwari R., Sriwastawa B., Bhati L., Pandey S., Pandey P., et al. Drug delivery systems: an updated review. Int J Pharm Investig 2012, 2:2-11.
2. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992, 31:205-213.
3. El-Telbany A., Ma P.C. Cancer genes in lung cancer: racial disparities: are there any?. Genes Cancer 2012, 3:467-480.
4. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98:2603-2614.
5. Green D.R. Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698.
6. Martinou J.C., Desagher S., Antonsson B. Cytochrome c release from mitochondria: all or nothing. Nat Cell Biol 2000, 2:E41-E43.
7. Zimmermann K.C., Bonzon C., Green D.R. The machinery of programmed cell death. Pharmacol Ther 2001, 92:57-70.
8. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
9. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999, 68:383-424.
10. Biasutto L., Dong L.F., Zoratti M., Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion 2010, 10:670-681.
11. Nevozhay D., Kanska U., Budzynska R., Boratynski J. Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases. Postepy Hig Med Dosw 2007, 61:350-360.
12. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32:3285-3302.
13. Pan J., Feng S.S. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 2008, 29:2663-2672.
14. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31:7748-7757.
15. Murphy M.P. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol 1997, 15:326-330.
16. Murphy M.P. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta 2008, 1777:1028-1031.
17. Millard M., Pathania D., Shabaik Y., Taheri L., Deng J., Neamati N. Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. PloS One 2010, 5.
18. Yamada Y., Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 2008, 60:1439-1462.
19. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
20. Andre N., Braguer D., Brasseur G., Goncalves A., Lemesle-Meunier D., Guise S., et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res 2000, 60:5349-5353.
21. Varbiro G., Veres B., Gallyas F., Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med 2001, 31:548-558.
22. Andre N., Carre M., Brasseur G., Pourroy B., Kovacic H., Briand C., et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 2002, 532:256-260.
23. Surapaneni M.S., Das S.K., Das N.G. Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol 2012, 2012:623139.
24. Cuchelkar V., Kopeckova P., Kopecek J. Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. Mol Pharm 2008, 5:776-786.
25. Duncanson W.J., Figa M.A., Hallock K., Zalipsky S., Hamilton J.A., Wong J.Y. Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. Biomaterials 2007, 28:4991-4999.
26. Liu Y., Lu W.L., Guo J., Du J., Li T., Wu J.W., et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 2008, 129:18-25.
27. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
28. Li R.J., Ying X., Zhang Y., Ju R.J., Wang X.X., Yao H.J., et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release 2011, 149:281-291.
29. Griffioen K.J., Ghribi O., Fox N., Savory J., DeWitt D.A. Aluminum maltolate-induced toxicity in NT2 cells occurs through apoptosis and includes cytochrome c release. Neurotoxicology 2004, 25:859-867.
30. Pozo-Guisado E., Merino J.M., Mulero-Navarro S., Lorenzo-Benayas M.J., Centeno F., Alvarez-Barrientos A., et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005, 115:74-84.
31. Wang X.X., Li Y.B., Yao H.J., Ju R.J., Zhang Y., Li R.J., et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011, 32:5673-5687.
32. Biswas S., Dodwadkar N.S., Deshpande P.P., Torchilin V.P. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release 2012, 159:393-402.
33. Biswas S., Dodwadkar N.S., Piroyan A., Torchilin V.P. Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials 2012, 33:4773-4782.
34. Cheng G., Lopez M., Zielonka J., Hauser A.D., Joseph J., McAllister D., et al. Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells. Cancer Biol Ther 2011, 12:707-717.
35. Zhang Z., Yang X., Feng S.S. Copolymer technology for advanced nanomedicine. Nanomedicine (Lond) 2011, 6:583-587.
36. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
37. Wadhwa R., Colgin L., Yaguchi T., Taira K., Reddel R.R., Kaul S.C. Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo. Cancer Res 2002, 62:4434-4438.
38. Muthu M.S., Kulkarni S.A., Xiong J., Feng S.S. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm 2011, 421:332-340.
39. Varma M.V., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005, 25:445-453.
40. Collnot E.M., Baldes C., Schaefer U.F., Edgar K.J., Wempe M.F., Lehr C.M. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 2010, 7:642-651.
41. Youk H.J., Lee E., Choi M.K., Lee Y.J., Chung J.H., Kim S.H., et al. Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J Control Release 2005, 107:43-52.
42. Li P.Y., Lai P.S., Hung W.C., Syu W.J. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010, 11:2576-2582.
43. Garcia-Saez A.J. The secrets of the Bcl-2 family. Cell Death Differ 2012, 19:1733-1740.
44. Rohlena J., Dong L.F., Ralph S.J., Neuzil J. Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid Redox Signal 2011, 15:2951-2974.